Copertina

Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Kexu Yang, Wenfang Liu, Yang Lin, Shan Jing, Xiaoyi Sun, Meng Fu, Xi Li, Ting Zhang, Min Hu, Feng He, Jun Feng
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	British Journal of Clinical Pharmacology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Randomised, phase 1 evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of iptacopan in healthy volunteers
di: Irina Baltcheva, et al.
Pubblicazione: (2026)

Effect of food on pharmacokinetics of ACC017, a novel HIV‐1 integrase inhibitor, in healthy adult subjects
di: C. Hu, et al.
Pubblicazione: (2025)

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
di: Yuhao Wang, et al.
Pubblicazione: (2025)

Safety and pharmacokinetics of a novel potent GABA analogue crisugabalin in Chinese subjects with various degrees of renal impairment
di: Shibeilei Lin, et al.
Pubblicazione: (2025)

Effect of fluconazole on the pharmacokinetics of ainuovirine in healthy adult subjects
Pubblicazione: (2024)

JAK–STAT inhibitory effect of IN‐115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine
di: Jae‐Hun Ahn, et al.
Pubblicazione: (2025)

Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects
di: Zi‐yi Zhou, et al.
Pubblicazione: (2026)

Safety, pharmacokinetics and pharmacodynamics of NXC736, a novel sphingosine‐1‐phosphate receptor modulator
di: Woo Kyung Chung, et al.
Pubblicazione: (2026)

Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure
di: Juliane Rascher, et al.
Pubblicazione: (2024)

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants
di: Mohammad Ghasemi, et al.
Pubblicazione: (2025)

Clinical study of the pharmacokinetics and pharmacodynamics of Xininurad tablets in patients with renal impairment
di: Xiaoni Wang, et al.
Pubblicazione: (2025)

C‐model: A comprehensive enhanced pharmacokinetic/pharmacodynamic simulation environment targeting the complement system
di: Lucía Alfonso‐González, et al.
Pubblicazione: (2025)

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
di: Jean‐Yves Gillon, et al.
Pubblicazione: (2025)

A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects
di: Yusuke Tadayasu, et al.
Pubblicazione: (2024)

Development of a novel tyrosine kinase 2 inhibitor ARTS‐011 and its first‐in‐human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effects
di: Zhili Jin, et al.
Pubblicazione: (2026)

Personalized parathyroid hormone therapy for hypoparathyroidism: Insights from pharmacokinetic‐pharmacodynamic modelling
di: Maira Visscher, et al.
Pubblicazione: (2024)

Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants
di: Clifford G. Banda, et al.
Pubblicazione: (2024)

Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study
di: Hiromitsu Imai, et al.
Pubblicazione: (2024)

Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673
di: Yue Wu, et al.
Pubblicazione: (2024)

Population pharmacokinetics and pharmacodynamics of intraperitoneal aerosolized nanoparticle albumin‐bound paclitaxel (nab‐PTX) and metabolites
di: Pieter‐Jan De Sutter, et al.
Pubblicazione: (2026)

Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia
di: Jona Joachim, et al.
Pubblicazione: (2024)

First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367
di: Andrea Kuemmerle, et al.
Pubblicazione: (2025)

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects
di: Marije E. Otto, et al.
Pubblicazione: (2026)

Single‐dose pharmacokinetics and safety of ACC017, a novel HIV integrase inhibitor, in healthy adult participants: A first‐in‐human study
di: C. Hu, et al.
Pubblicazione: (2025)

A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers
di: Yanina Hiriart, et al.
Pubblicazione: (2024)

The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat
di: Chandrali S. Bhattacharya, et al.
Pubblicazione: (2024)

The NADPH oxidase inhibitor Vas2870 prevents myocyte ferroptosis and improves cardiac remodelling and function in doxorubicin‐induced cardiomyopathy
di: Jing Wang, et al.
Pubblicazione: (2026)

Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer
di: Yue Zhao, et al.
Pubblicazione: (2024)

Probability of pharmacokinetic/pharmacodynamic target attainment for different piperacillin/tazobactam dosing regimens in renally impaired patients in a non‐intensive care unit setting
di: Emma Dohmann, et al.
Pubblicazione: (2025)

Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection
Pubblicazione: (2024)

Pharmacokinetics and pharmacodynamics of intranasal insulin in a rat brain
di: Jelena Osmanovic Barilar, et al.
Pubblicazione: (2025)

The sodium–glucose co‐transporter 2 inhibitor, empagliflozin, attenuates pulmonary vascular remodelling by inhibiting the phosphorylation of PDGF receptor‐β
di: Ting‐ting Lyu, et al.
Pubblicazione: (2025)

Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease
di: Muhammad Waqas Sadiq, et al.
Pubblicazione: (2024)

Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial
di: Alexander Hincker, et al.
Pubblicazione: (2024)

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults
di: Hechuan Wang, et al.
Pubblicazione: (2026)

A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults
di: Shamia L. Faison, et al.
Pubblicazione: (2025)

A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
di: Jane Knöchel, et al.
Pubblicazione: (2024)

Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG‐750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG‐745)
di: Byungwook Kim, et al.
Pubblicazione: (2024)

Reference range of rivaroxaban‐calibrated anti‐Xa activity in Chinese children with giant coronary artery aneurysms after KawasakI disease: insights from a population pharmacokinetic and pharmacodynamic analysis
di: Bijue Liu, et al.
Pubblicazione: (2025)

Characterizing local and systemic exposure to clobetasol propionate in healthy subjects and patients with atopic dermatitis
di: Janna K. Duong, et al.
Pubblicazione: (2025)